slides · global inventory
Disclaimer
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,127
Current window 32,161-32,190
Pages 1,371
Rows per page 30
Component
32,161-32,190 of 41,127
06
The slide uses a process-flow diagram to contrast personalized autologous therapy with off-the-shelf bispecific therapy.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
08
The slide outlines a partnership structure involving three distinct therapeutic approaches and a financial deal structure.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a list-based comparison to show market potential for specific drug targets.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
19
The table highlights key clinical metrics including ORR, cORR, mDOR, and mFU for various patient subgroups.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
22
Data cut-off Sep 30, 2023. Includes extensive footnotes regarding methodology and specific patient cases.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
23
Includes waterfall plot for BOR and spider plot for response over time. Data cut-off Sep 30, 2023.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
24
The slide uses a matrix structure to define the patient population and market opportunity.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
29
Data cut-off Sep 30, 2023. Slide 29.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
31
Includes p-values for statistical significance across four distinct clinical metrics.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
34
Uses a ridge plot (joyplot) to visualize distribution of PRAME expression across 7 cancer types.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
37
The table uses a multi-step funnel approach to arrive at the final patient population count.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
48
The chart uses a broken axis to show early time points and late-stage tumor volume divergence.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
54
The slide uses a process flow diagram to illustrate the transition from dose escalation to expansion cohorts.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
74
Data cut-off Sep 30, 2023. N=28 patients.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
75
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
02
Immix Biopharma | Investor Presentation Deck | 60 slidesImmix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
06
Includes a biological process diagram showing B-cell development and target markers (CD19, CD20, BCMA).Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
16
Includes comparative bar charts for transduction efficiency and toxicity markers, and flow cytometry data for anti-exhaustion.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
17
The slide uses a multi-panel line chart with timeline bars to contrast clinical outcomes.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
18
The chart demonstrates a clear inverse relationship where the spike in HBI0101 cells corresponds to a rapid decline in dFLC levels, stabilizing around the 30-day mark.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Golden Circle1 hit
27
The slide uses a standard pharmaceutical pipeline table format, categorizing assets by clinical vs. preclinical status and highlighting specific clinical trial results and regulatory designations.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
28
Includes a comparison table of clinical outcomes (ORR/CR/sCR) between NXC-201 and competitors.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
02
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
27
The slide uses a standard pharmaceutical pipeline table format, categorizing by clinical vs preclinical status and highlighting specific regulatory designations and trial results.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market Sizing1 hit
31
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
33
The table compares NXC-201 against various CAR-T therapies, highlighting patient characteristics, efficacy (ORR, CR), and safety (ICANS, CRS) metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
34
The slide uses a side-by-side comparison of two disease indications, showing clinical results, relevant competitor benchmarks, and market size.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
35
The chart demonstrates deepening clinical response over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
36
The table displays clinical trial data for NXC-201, specifically focusing on safety profiles and management interventions.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
64
The slide uses a bar-grouped chart format to highlight the efficacy gap between established treatments and placebo.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit